{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-067468","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2023-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.578573+00:00","generated_at":"2026-06-07T18:37:11.139188+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"EyePoint reports positive Phase 2 DAVIO 2 topline for EYP-1901 in wet AMD; all endpoints met","bullets":["Both EYP-1901 doses (2mg and 3mg) achieved non-inferiority in BCVA vs aflibercept (difference of -0.3 and -0.4 letters).","Over 80% reduction in treatment burden; 65%/64% of eyes supplement-free up to six months for 2mg/3mg.","No EYP-1901-related ocular or systemic SAEs; favorable safety profile.","Phase 3 pivotal trial for wet AMD planned for H2 2024; DME trial starts Q1 2024; NPDR data Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-067468","json":"https://secwatch.observer/filing/0000950170-23-067468.json","markdown":"https://secwatch.observer/filing/0000950170-23-067468.md","text":"https://secwatch.observer/filing/0000950170-23-067468.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017023067468/0000950170-23-067468-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017023067468/eypt-20231204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T18:37:11.139188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}